Boulos Mansour
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Boulos Mansour has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Michael Michal
Department of Pathology, Faculty of Medicine in Plzen, Charles University, Prague, Czech Republic
10 shared publications - Carina A. Dehner
Department of Pathology and Laboratory Medicine Hospital of the University of Pennsylvania Philadelphia PA USA
9 shared publications - Cristina R. Antonescu
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
9 shared publications - Faizan Malik
Department of Pathology, St. Jude Children’s Research Hospital, Memphis, USA
9 shared publications - Fredrik Petersson
Department of Pathology, National University Hospital, 5 Lower Kent Ridge Road, Singapore, 119074, Singapore.
9 shared publications - Isidro Machado
Pathology Department, University of Valencia, 46010 Valencia, Spain
9 shared publications
Latest Publications
- 22 May 2026
- Published by Springer Nature in Virchows Archiv
- Vol. 489 (1) , 1-9
ACTIN::MITF-rearranged tumor: a distinctive entity or a cutaneous PEComa with MITF alterations? A clinicopathological and molecular study of additional 5 cases
ACTIN::MITF-rearranged tumors represent a poorly defined subset within the expanding spectrum of MITF pathway–activated cutaneous mesenchymal neoplasms. These tumors are of uncertain lineage, with ongoing debate as to whether they are of melanocytic or, more likely, non-melanocytic origin. They are characterized by recurrent genomic rearrangements that activate the MITF signaling axis and result in MITF overexpression. To date, only ten cases have been reported, and their nosologic classification—as well as their relationship to other entities, particularly primary cutaneous perivascular epithelioid cell tumors (pcPEComas)—remains uncertain. To further characterize this entity, we identified five additional cases (3 females, 2 males; mean age 55.8 years, median 61, range 22–81), all arising on the lower extremities and measuring 0.8–3 cm. Follow-up (n = 2) revealed one local recurrence with survival at 122 months (disease status unknown) and one patient alive at 14 months with indeterminate but likely benign pulmonary nodules. Histologically, tumors were non-circumscribed dermal nodules extending to the dermoepidermal junction without epidermal involvement and displaying infiltrative and/or expansile borders. They consisted predominantly of solid sheets of epithelioid cells with focal spindle areas dissecting collagen in a characteristic “checkerboard-like” pattern. Paraganglioma-like and perivascular architectures were observed. Cytologic atypia was mild; a single mitotic figure was identified in one case; necrosis, lymphovascular, and perineural invasion were absent. All tumors showed diffuse MITF and multifocal HMB-45 expression. GPNMB and PRAME were positive in both tested cases. RNA-based sequencing demonstrated in-frame ACTG1::MITF fusions in four tumors and an ACTB::MITF fusion in one; MITF rearrangement was confirmed by break-apart FISH in two. We additionally reviewed the literature on primary cutaneous PEComas and compared their clinicopathologic features with those of ACTIN::MITF-rearranged tumors. This study expands the clinicopathologic and molecular spectrum of ACTIN::MITF-rearranged tumors and further explores their relationship to cutaneous PEComas.
- 22 May 2026
- Published by Springer Nature in Virchows Archiv
- Vol. 489 (1) , 1-9
ACTIN::MITF-rearranged tumor: a distinctive entity or a cutaneous PEComa with MITF alterations? A clinicopathological and molecular study of additional 5 cases
ACTIN::MITF-rearranged tumors represent a poorly defined subset within the expanding spectrum of MITF pathway–activated cutaneous mesenchymal neoplasms. These tumors are of uncertain lineage, with ongoing debate as to whether they are of melanocytic or, more likely, non-melanocytic origin. They are characterized by recurrent genomic rearrangements that activate the MITF signaling axis and result in MITF overexpression. To date, only ten cases have been reported, and their nosologic classification—as well as their relationship to other entities, particularly primary cutaneous perivascular epithelioid cell tumors (pcPEComas)—remains uncertain. To further characterize this entity, we identified five additional cases (3 females, 2 males; mean age 55.8 years, median 61, range 22–81), all arising on the lower extremities and measuring 0.8–3 cm. Follow-up (n = 2) revealed one local recurrence with survival at 122 months (disease status unknown) and one patient alive at 14 months with indeterminate but likely benign pulmonary nodules. Histologically, tumors were non-circumscribed dermal nodules extending to the dermoepidermal junction without epidermal involvement and displaying infiltrative and/or expansile borders. They consisted predominantly of solid sheets of epithelioid cells with focal spindle areas dissecting collagen in a characteristic “checkerboard-like” pattern. Paraganglioma-like and perivascular architectures were observed. Cytologic atypia was mild; a single mitotic figure was identified in one case; necrosis, lymphovascular, and perineural invasion were absent. All tumors showed diffuse MITF and multifocal HMB-45 expression. GPNMB and PRAME were positive in both tested cases. RNA-based sequencing demonstrated in-frame ACTG1::MITF fusions in four tumors and an ACTB::MITF fusion in one; MITF rearrangement was confirmed by break-apart FISH in two. We additionally reviewed the literature on primary cutaneous PEComas and compared their clinicopathologic features with those of ACTIN::MITF-rearranged tumors. This study expands the clinicopathologic and molecular spectrum of ACTIN::MITF-rearranged tumors and further explores their relationship to cutaneous PEComas.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Data from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Purpose:Fusion-positive myoepithelial tumors (MET) are clinicopathologically heterogeneous and variably termed mixed tumors and myoepithelial carcinomas. As FET-rearranged METs lack ductal/epithelial differentiation, we test whether FET-rearranged METs are epigenetically distinct from adnexal PLAG1-rearranged METs, which we hypothesize to be analogues of salivary gland METs.Experimental Design:DNA methylation profiling from a multi-institutional cohort of 52 fusion-positive skin, soft-tissue, and bone MET cases was performed and compared with diverse tumor types, including salivary METs. The MET subgroups harbored EWSR1::KLF15, EWSR1/FUS::KLF17, EWSR1::PBX1, EWSR1::PBX3, EWSR1/FUS::POU5F1, SS18::POU5F1, EWSR1::ZNF444, and PLAG1 rearrangements. Pooled clinicopathologic and outcome analysis with new and published cases (total 185) was performed.Results:The MET subgroups showed significant heterogeneity in age, site, and histology. Specifically, EWSR1::KLF15 METs affected predominantly young children (<5 years); EWSR1::PBX1/PBX3 METs were enriched in skin/bone; and EWSR1/FUS::POU5F1, SS18::POU5F1, and EWSR1::KLF15 METs tended to display malignant histology. Conversely, PLAG1-rearranged tumors were predominantly benign, arising in older adults and located in the skin. DNA methylation profiling revealed that FET-rearranged METs were epigenetically related to SS18::POU5F1 METs and FET::NFATC2 sarcomas but entirely distinct from PLAG1-rearranged adnexal and salivary METs. Histologic features were correlated with the degree of genome-wide copy-number variation. The median disease-specific survival was shortest in SS18::POU5F1 (31 months), EWSR1::PBX3 (38 months), and EWSR1::KLF15 (45 months) METs. On multivariate analysis, age <25 years was a significant predictor of worse progression-free survival.Conclusions:FET-rearranged METs are epigenetically unrelated to cutaneous and salivary gland METs, and their malignant counterparts are best classified as sarcomas rather than carcinomas.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Purpose:Fusion-positive myoepithelial tumors (MET) are clinicopathologically heterogeneous and variably termed mixed tumors and myoepithelial carcinomas. As FET-rearranged METs lack ductal/epithelial differentiation, we test whether FET-rearranged METs are epigenetically distinct from adnexal PLAG1-rearranged METs, which we hypothesize to be analogues of salivary gland METs.Experimental Design:DNA methylation profiling from a multi-institutional cohort of 52 fusion-positive skin, soft-tissue, and bone MET cases was performed and compared with diverse tumor types, including salivary METs. The MET subgroups harbored EWSR1::KLF15, EWSR1/FUS::KLF17, EWSR1::PBX1, EWSR1::PBX3, EWSR1/FUS::POU5F1, SS18::POU5F1, EWSR1::ZNF444, and PLAG1 rearrangements. Pooled clinicopathologic and outcome analysis with new and published cases (total 185) was performed.Results:The MET subgroups showed significant heterogeneity in age, site, and histology. Specifically, EWSR1::KLF15 METs affected predominantly young children (<5 years); EWSR1::PBX1/PBX3 METs were enriched in skin/bone; and EWSR1/FUS::POU5F1, SS18::POU5F1, and EWSR1::KLF15 METs tended to display malignant histology. Conversely, PLAG1-rearranged tumors were predominantly benign, arising in older adults and located in the skin. DNA methylation profiling revealed that FET-rearranged METs were epigenetically related to SS18::POU5F1 METs and FET::NFATC2 sarcomas but entirely distinct from PLAG1-rearranged adnexal and salivary METs. Histologic features were correlated with the degree of genome-wide copy-number variation. The median disease-specific survival was shortest in SS18::POU5F1 (31 months), EWSR1::PBX3 (38 months), and EWSR1::KLF15 (45 months) METs. On multivariate analysis, age <25 years was a significant predictor of worse progression-free survival.Conclusions:FET-rearranged METs are epigenetically unrelated to cutaneous and salivary gland METs, and their malignant counterparts are best classified as sarcomas rather than carcinomas.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S2. Unsupervised hierarchical clustering heatmap of DNA methylation beta values (top 5000 by variance) across selected tumor types. Shown are the genes corresponding to the top 100 cpg sites.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S2. Unsupervised hierarchical clustering heatmap of DNA methylation beta values (top 5000 by variance) across selected tumor types. Shown are the genes corresponding to the top 100 cpg sites.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S10 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Table S1. Clinicopathologic features of new and published cases of EWSR1/FUS::POU5F1-rearranged MET Suppl. Table S2. Clinicopathologic features of new and published cases of SS18::PBX1/3-rearranged MET Suppl. Table S3. Clinicopathologic features of new and published cases of EWSR1::KLF15-rearranged MET Suppl. Table S4. Clinicopathologic features of new and published cases of EWSR1/FUS::KLF17-rearranged MET Suppl. Table S5. Clinicopathologic features of new and published cases of EWSR1::ZNF444-rearranged MET Suppl. Table S6. Clinicopathologic features of new and published cases of EWSR1::PBX1/3-rearranged MET Suppl. Table S7. Clinicopathologic features of new and published cases of PLAG1-altered MET Suppl. Table S8. Clinicopathologic summary of fusion-positive myoepithelial tumors (new and published cases) Suppl. Table S9. Significant differentially methylated regions: ENT and cutaneous PLAG1-rearranged vs FET-rearranged myoepithelial tumors Suppl. Table S10. Univariate and Multivariate Survival Analysis for Disease-specific Survival (DSS) and Progression-free Survival (PFS)
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S10 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Table S1. Clinicopathologic features of new and published cases of EWSR1/FUS::POU5F1-rearranged MET Suppl. Table S2. Clinicopathologic features of new and published cases of SS18::PBX1/3-rearranged MET Suppl. Table S3. Clinicopathologic features of new and published cases of EWSR1::KLF15-rearranged MET Suppl. Table S4. Clinicopathologic features of new and published cases of EWSR1/FUS::KLF17-rearranged MET Suppl. Table S5. Clinicopathologic features of new and published cases of EWSR1::ZNF444-rearranged MET Suppl. Table S6. Clinicopathologic features of new and published cases of EWSR1::PBX1/3-rearranged MET Suppl. Table S7. Clinicopathologic features of new and published cases of PLAG1-altered MET Suppl. Table S8. Clinicopathologic summary of fusion-positive myoepithelial tumors (new and published cases) Suppl. Table S9. Significant differentially methylated regions: ENT and cutaneous PLAG1-rearranged vs FET-rearranged myoepithelial tumors Suppl. Table S10. Univariate and Multivariate Survival Analysis for Disease-specific Survival (DSS) and Progression-free Survival (PFS)
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S5. Kaplan–Meier curves illustrating disease-specific survival (DSS) stratified by age group (A) and tumor size (B). Forest plots illustrating multivariate Cox-regression analysis of progression-free survival (C).
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S5. Kaplan–Meier curves illustrating disease-specific survival (DSS) stratified by age group (A) and tumor size (B). Forest plots illustrating multivariate Cox-regression analysis of progression-free survival (C).
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S6. Kaplan–Meier curves illustrating progression-free survival (PFS) stratified by age group (A) and tumor size (B). Forest plots illustrating multivariate Cox-regression analysis of progression-free survival (C).
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S6. Kaplan–Meier curves illustrating progression-free survival (PFS) stratified by age group (A) and tumor size (B). Forest plots illustrating multivariate Cox-regression analysis of progression-free survival (C).
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S4. Differentially methylated regions M values between salivary/PLAG1-rearranged vs FET-rearranged myoepithelial tumors.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S4. Differentially methylated regions M values between salivary/PLAG1-rearranged vs FET-rearranged myoepithelial tumors.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S3. Unsupervised hierarchical clustering of DNA methylation beta values (top 1000 by variance) across FET-rearranged myoepithelial tumors and NFATC2 -rearranged sarcoma. Shown are the genes corresponding to top 200 cpg sites by variance.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S3. Unsupervised hierarchical clustering of DNA methylation beta values (top 1000 by variance) across FET-rearranged myoepithelial tumors and NFATC2 -rearranged sarcoma. Shown are the genes corresponding to top 200 cpg sites by variance.
- Open Access
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S1. Scree plot (A). PCA plot before (B) and after (C) dimensionality reduction by UMAP.
- 4 February 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1-Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Suppl. Figure S1. Scree plot (A). PCA plot before (B) and after (C) dimensionality reduction by UMAP.
- 4 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (3) , 628-644
FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1 -Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Purpose: Fusion-positive myoepithelial tumors (MET) are clinicopathologically heterogeneous and variably termed mixed tumors and myoepithelial carcinomas. As FET-rearranged METs lack ductal/epithelial differentiation, we test whether FET-rearranged METs are epigenetically distinct from adnexal PLAG1-rearranged METs, which we hypothesize to be analogues of salivary gland METs. Experimental Design: DNA methylation profiling from a multi-institutional cohort of 52 fusion-positive skin, soft-tissue, and bone MET cases was performed and compared with diverse tumor types, including salivary METs. The MET subgroups harbored EWSR1::KLF15, EWSR1/FUS::KLF17, EWSR1::PBX1, EWSR1::PBX3, EWSR1/FUS::POU5F1, SS18::POU5F1, EWSR1::ZNF444, and PLAG1 rearrangements. Pooled clinicopathologic and outcome analysis with new and published cases (total 185) was performed. Results: The MET subgroups showed significant heterogeneity in age, site, and histology. Specifically, EWSR1::KLF15 METs affected predominantly young children (<5 years); EWSR1::PBX1/PBX3 METs were enriched in skin/bone; and EWSR1/FUS::POU5F1, SS18::POU5F1, and EWSR1::KLF15 METs tended to display malignant histology. Conversely, PLAG1-rearranged tumors were predominantly benign, arising in older adults and located in the skin. DNA methylation profiling revealed that FET-rearranged METs were epigenetically related to SS18::POU5F1 METs and FET::NFATC2 sarcomas but entirely distinct from PLAG1-rearranged adnexal and salivary METs. Histologic features were correlated with the degree of genome-wide copy-number variation. The median disease-specific survival was shortest in SS18::POU5F1 (31 months), EWSR1::PBX3 (38 months), and EWSR1::KLF15 (45 months) METs. On multivariate analysis, age <25 years was a significant predictor of worse progression-free survival. Conclusions: FET-rearranged METs are epigenetically unrelated to cutaneous and salivary gland METs, and their malignant counterparts are best classified as sarcomas rather than carcinomas.
- 4 December 2025
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (3) , 628-644
FET-Rearranged Myoepithelial Tumors Are Clinically Heterogeneous and Epigenetically Distinct from PLAG1 -Rearranged Adnexal and Salivary Gland Myoepithelial Tumors
Purpose: Fusion-positive myoepithelial tumors (MET) are clinicopathologically heterogeneous and variably termed mixed tumors and myoepithelial carcinomas. As FET-rearranged METs lack ductal/epithelial differentiation, we test whether FET-rearranged METs are epigenetically distinct from adnexal PLAG1-rearranged METs, which we hypothesize to be analogues of salivary gland METs. Experimental Design: DNA methylation profiling from a multi-institutional cohort of 52 fusion-positive skin, soft-tissue, and bone MET cases was performed and compared with diverse tumor types, including salivary METs. The MET subgroups harbored EWSR1::KLF15, EWSR1/FUS::KLF17, EWSR1::PBX1, EWSR1::PBX3, EWSR1/FUS::POU5F1, SS18::POU5F1, EWSR1::ZNF444, and PLAG1 rearrangements. Pooled clinicopathologic and outcome analysis with new and published cases (total 185) was performed. Results: The MET subgroups showed significant heterogeneity in age, site, and histology. Specifically, EWSR1::KLF15 METs affected predominantly young children (<5 years); EWSR1::PBX1/PBX3 METs were enriched in skin/bone; and EWSR1/FUS::POU5F1, SS18::POU5F1, and EWSR1::KLF15 METs tended to display malignant histology. Conversely, PLAG1-rearranged tumors were predominantly benign, arising in older adults and located in the skin. DNA methylation profiling revealed that FET-rearranged METs were epigenetically related to SS18::POU5F1 METs and FET::NFATC2 sarcomas but entirely distinct from PLAG1-rearranged adnexal and salivary METs. Histologic features were correlated with the degree of genome-wide copy-number variation. The median disease-specific survival was shortest in SS18::POU5F1 (31 months), EWSR1::PBX3 (38 months), and EWSR1::KLF15 (45 months) METs. On multivariate analysis, age <25 years was a significant predictor of worse progression-free survival. Conclusions: FET-rearranged METs are epigenetically unrelated to cutaneous and salivary gland METs, and their malignant counterparts are best classified as sarcomas rather than carcinomas.